Italian Drug Policy: Ethical Aims of Essential Assistance Levels

Health Care Analysis

Volumn 11, Issue 4, 2003, Pages 279-286

  Bernardi, Alessandra ^a,b   Pegoraro, Renzo ^a  

^a Fondazione Lanza   (Italy)

^b Fondazione Lanza   (Italy)

Author keywords

Essential Assistance Levels (LEA); Ethical aims; Italian drug policy; Pharmaceutical expenditure; Rivastigmine; Statins

Indexed keywords

ANALGESIC AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; OPIATE; PRAVASTATIN; RIVASTIGMINE; SIMVASTATIN; STATINE DERIVATIVE;

ALZHEIMER DISEASE; COST BENEFIT ANALYSIS; DRUG COST; DRUG FORMULARY; DRUG INDICATION; DRUG LEGISLATION; FAMILIAL HYPERCHOLESTEROLEMIA; GOVERNMENT; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH SERVICE; HUMAN; HYPERCHOLESTEROLEMIA; ITALY; LAW; PROSPECTIVE PAYMENT; REIMBURSEMENT; REVIEW; SIDE EFFECT;

HEALTH CARE AND PUBLIC HEALTH;

ANTICHOLESTEREMIC AGENTS; CARBAMATES; CHOLINESTERASE INHIBITORS; DRUG COSTS; DRUGS, ESSENTIAL; FORMULARIES; HEALTH CARE COSTS; HEALTH CARE RATIONING; HEALTH POLICY; HEPTANOIC ACIDS; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT; ITALY; MEDICAL ASSISTANCE; NATIONAL HEALTH PROGRAMS; PHENYLCARBAMATES; PYRROLES;

EID: 1642539129     PISSN: 10653058     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:HCAN.0000010056.05684.22     Document Type: Review

References (11)

1. Atella, V. (2000) Drug Cost Containment Policies in Italy: Are They Really Effective in the Long-Run? The Case of Minimum Reference Price. Health Policy 50, 197-218.
2. Begaud, B., Bergman, U., Eichler, H. G., Leufkens, H. G., and Meier, P. J. (2002) Drug Reimbursement: Indicators of Inappropriate Resource Allocation. British Journal of Clinical Pharmacology 54, 528-534.
3. Braga, M., and Cislaghi, C. (2002) The Evaluation of Efficacy and Efficiency in the Health Care Sector: Separate or Integrated Moments? Annali di Igiene 14, 409-418.
4. Fattore, G., and Jommi, C. (1998) The New Pharmaceutical Policy in Italy. Health Policy 46, 21-41.
5. Pavenik, N. (2002) Do Pharmaceutical Price Respond to Potential Patient Out-of-Pocket Expenses? RAND Journal of ECONOMICS 33, 469-487.
6. Rice, N., and Smith, P. C. (2000) Capitation and Risk Adjustment in Health Care. Health Care Management Science 3, 73-75.
7. Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M., Wun, C. C., Davis, B. R., and Braunwald, E. (1996) The Effect of Pravastatin on Coronary Events After Myocardical Infarction in Patients With Average Cholesterol Levels. Cholesterol and Recurrent Events Trial Investigators. New England Journal of Medicine 335, 1001-1009.
8. Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., and Packard, C. J., The West of Scotland Coronary Prevention Study Group. (1995) Prevention of Coronary Heart Disease With Pravastatin in Men With Hypercholesterolemia. New England Journal of Medicine 333, 1301-1307.
9. The Long Term Interventions With Pravastatin in Ischemic Disease (LIPID) Study Group. (1998) Prevention of Cardiovascular Events and Death With Pravastatin in Patients With Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels. New England Journal of Medicine 339, 1349.
10. The Scandinavian Simvastatin Survival Study Group. (1994) Randomised Trial of Cholesterol Lowering in 4.444 Patients With Coronary Heart Disease. The Scandinavian Simvastatin Survival Study. Lancet 344, 1383.
11. Trabucchi, M. (1999) An Economic Perspective on Alzheimer's Disease. Journal of Geriatric Psychiatry and Neurology 12, 29-38.